Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study.

Autor: García-Grimshaw M; Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Ceballos-Liceaga SE; Secretaría de Salud, Gobierno de México, Mexico., Hernández-Vanegas LE; Department of Neurology, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico., Núñez I; Department of Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Hernández-Valdivia N; Secretaría de Salud, Gobierno de México, Mexico., Carrillo-García DA; Secretaría de Salud, Gobierno de México, Mexico., Michel-Chávez A; Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Galnares-Olalde JA; Department of Neurology, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico., Carbajal-Sandoval G; Secretaría de Salud, Gobierno de México, Mexico., Del Mar Saniger-Alba M; Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Carrillo-Mezo RA; Department of Neuroradiology, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico., Fragoso-Saavedra S; Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Programa de Estudios Combinados en Medicina (MD/PhD program), Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico., Espino-Ojeda A; Instituto Mexicano del Seguro Social, Mexico City, Mexico., Blaisdell-Vidal C; Instituto Mexicano del Seguro Social, Mexico City, Mexico., Mosqueda-Gómez JL; Hospital Regional de Alta Especialidad del Bajío, León, Mexico., Sierra-Madero J; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Pérez-Padilla R; Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico., Alomía-Zegarra JL; Secretaría de Salud, Gobierno de México, Mexico., López-Gatell H; Secretaría de Salud, Gobierno de México, Mexico., Díaz-Ortega JL; Centro Nacional para la Salud de la Infancia y la Adolescencia, Mexico City, Mexico., Reyes-Terán G; Comisión Coordinadora de Institutos Nacionales de Salud y Hospitales de Alta Especialidad, Mexico City, Mexico., Arauz A; Secretaría de Salud, Gobierno de México, Mexico., Valdés-Ferrer SI; Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Secretaría de Salud, Gobierno de México, Mexico; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Feinstein Institutes for Medical Research, Manhasset, NY, USA. Electronic address: sergio.valdesf@incmnsz.mx.
Jazyk: angličtina
Zdroj: Clinical immunology (Orlando, Fla.) [Clin Immunol] 2021 Aug; Vol. 229, pp. 108786. Date of Electronic Publication: 2021 Jun 18.
DOI: 10.1016/j.clim.2021.108786
Abstrakt: mRNA vaccines against SARS-CoV-2 are remarkably effective. Limited information exists about the incidence of adverse events following immunization (AEFI) with their use. We conducted a prospective observational study including data from 704,003 first-doses recipients; 6536 AEFI were reported, of whom 65.1% had at least one neurologic AEFI (non-serious 99.6%). Thirty-three serious events were reported; 17 (51.5%) were neurologic (observed frequency, 2.4/100,000 doses). At the time of writing this report, 16/17 cases had been discharged without deaths. Our data suggest that the BNT162b2 mRNA COVID-19 vaccine is safe; its individual and societal benefits outweigh the low percentage of serious neurologic AEFI. This information should help to dissipate hesitancy towards this new vaccine platform.
(Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE